Fine mapping spatiotemporal mechanisms of genetic variants underlying cardiac traits and disease

Figures

• 

  Fig. 1. Gene and isoform eQTLs. a Barplot showing the number of eQTLs for eGenes (left) and eIsoforms (right). Colors represent the number of eGenes with primary and conditional eQTLs (up to five conditional signals). b Barplot showing the distribution of PPA for each of the five colocalization hypotheses. All the colocalizations associated with hypothesis 0, 1, and 2 were likely underpowered, thus they were labeled as “not resolved (NR)”. The 1421 eIsoforms whose associated gene did not have an eQTL were labeled as “no eGene”. c, d Examples of (c) eQTL signal for an eGene (B4GALT7) that colocalizes with PPA = 1 with the eQTL signal of one associated eIsoform and (d) eQTL signal for an eGene (RNH1) that does not colocalize with the eQTL signal of one associated eIsoform. In each plot, X axis represents the −log10 (eQTL p-value) for the associations between the genotype of each tested variant and gene expression, whereas the Y axis shows the −log10 (eQTL p-value) for the associations between the genotype of each tested variant and isoform use. e Enrichment of eGenes compared with eIsoforms for overlapping intergenic regions, introns, promoters, UTRs, splice donor sites, splice acceptor…

• 

  Fig. 2. Stage, organ, tissue, and cell type eQTLs. a, b Barplots showing the number of a eGenes and b eIsoforms associated with: cardiac stage (iPSC-CVPC or adult); organ (arteria or heart); tissue (atrial appendage, left ventricle, aorta or coronary artery); and cell type. Non-hatched bar sections represent eQTLs that are associated with the indicated stage, organ, tissue or cell type, and hatched sections represent specific eQTLs. c–e Examples of three association types between eQTLs and cardiac stage. For each eGene, boxplots (n = 966 samples) describe the normalized expression in iPSC-CVPCs (blue) and all other samples (i.e., adult cardiac samples; gray), grouped by genotype. The panels show examples of: c an eGene whose eQTL is shared across both cardiac stages; d an iPSC-CVPC-specific eQTL: the association between genotype and gene expression is only present in iPSC-CVPCs; and e iPSC-CVPC-associated eQTL: while the genotype is associated with gene expression in both iPSC-CVPCs and the adult samples, the eQTL is significantly stronger in iPSC-CVPCs. All five possible association types are shown in Supplementary Fig. 1. The boxplots were built as follows: upper and lower edges…

• 

  Fig. 3. eQTL signals associated with multiple genes. a Enrichment of eGenes that share the same eQTL signal with other eGenes or eIsoforms for having stage-, organ-, tissue- and cell type- eQTLs measured by linear regression analysis (n = 2778). Dots represent effect size and segments represent standard errors. Effect sizes, standard errors and p-values were measured using the lm function in R. b eGenes that share the same eQTL signals are enriched for being associated with same stage, organ, tissue, or cell type calculated using a permutation test. Dots represent Z-scores. c–h eQTL signals shared between a gene and its associated antisense RNA: c–e PAX8 and PAX8-AS1; f–h IRF1 and IRF1-AS1. c, f scatterplots showing the –log10 (eQTL p-value) for the gene (X axis; c: PAX8; f: IRF1) and for the antisense RNA (Y axis; c: PAX8-AS1; f: IRF1-AS1). d, e, g, h eQTL signal for the gene (in blue, panels d and g) and for the antisense RNA (in green, panels e and h).

• 

  Fig. 4. Manhattan plots showing the GWAS signals that colocalize with eQTLs. a–e Manhattan plots showing the GWAS signals for five cardiac traits. Among all genome-wide significant SNPs, the GWAS signals that colocalize with eQTLs for eGenes are highlighted in purple, with eQTLs for eIsoforms (light brown), with eQTL signals for both eGenes and eIsoforms (green), and those that do not colocalize with eQTLs are shown in turquoise. Horizontal dashed blue line represents the genome-wide significance threshold (GWAS p = 5 × 10−8).

• 

  Fig. 5. Colocalization between spatiotemporal eQTLs and cardiac GWAS. a Barplots showing the number of spatiotemporal eQTL signals that colocalize with cardiac GWAS signals. We observed 51 eGenes and 21 eIsoforms that were associated with one or more spatiotemporal categories colocalize with GWAS traits. Colors represent cardiac stage, organ, tissue, and cell type as described in the legend on the right. b–d Plots showing (b) −log10(p-value) for cardiac muscle- eQTL signal for SYNE2, c the GWAS signal for atrial fibrillation and d the PPA of each variant in the colocalization. The lead variant (i.e., the variant with highest PPA of being causal for both the eQTL and GWAS signals) is shown as a magenta diamond: all non-lead variants with PPA > 0.01 are shown as smaller red diamonds. The variant with the strongest p-value in the eQTL signal is shown as an orange diamond. e–g Line plots showing the enrichment of stage-, organ-, tissue- and cell-type- eQTLs in various GWAS traits: e pulse pressure; f pulse rate; and g atrial fibrillation (ICD10 code: I48). Enrichment is plotted as the log (odds ratio) (Y axis) over all PP-H4 thresholds (0.05 to 0.95, in 0.05 increments) of the eQTL signal…

• 

  Fig. 6. Fine mapping of stage and cell type- eQTLs colocalizing with cardiac traits. a–e Pie charts showing for each cardiac trait the distribution of SNPs in 99% credible sets. The colors indicate the number of SNPs and the numbers around the perimeter indicate the number of credible sets. f Pie chart showing the overlap between the lead SNP at each GWAS signal in the five cardiac traits and the index SNP for the GWAS signal in the GWAS catalog for the same trait. SNPs in high LD have R2 > 0.8 and SNPs in low LD have 0.2 ≤ R2 ≤ 0.8. g–o Plots showing −log10(p-value) eQTL signals (top row; panels g, j, m, p), the GWAS signals (middle row; panels h, k, n, q) and the PPA of each variant in the colocalization (bottom row; panels i, l, o, r) at four loci: (g–i) CEP68 expression and atrial fibrillation; j–l PRKG1 (isoform ENST00000643582.1_1) expression and pulse pressure; m–o FLCN expression and pulse rate; and p–r ACTN2 expression and pulse rate.